Drug intelligence / Profile preview

AAV9-CBA-luciferase

Development stage: Preclinical
Lead developer: University of North Carolina at Chapel Hill
Modality: Gene Therapies
Administration: Intravenous

Overview

AAV9-CBA-luciferase is a recombinant adeno-associated virus (AAV) vector of serotype 9 used as a reporter system in preclinical gene therapy research. It utilizes the ubiquitous Chicken Beta-Actin (CBA) promoter to drive the expression of the firefly luciferase transgene. This vector serves as a diagnostic and research tool for evaluating viral biodistribution, tissue tropism, and transduction efficiency across various organs, including the liver, brain, and skeletal muscle. Research conducted at the University of North Carolina at Chapel Hill has employed this vector to investigate how physiological states, such as exercise-induced changes in heart rate and circulation dynamics, influence the efficiency and precision of AAV-mediated gene delivery.

Other names: AAV9-CBA-LucAAV-9-CBA-LucAAV 9-CBA-Luc

Beyond the preview

Go deeper on AAV9-CBA-luciferase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV9-CBA-luciferase.

Explore the full profile